About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in the Denali team with a proposal to spin out the small-molecule drugs with ...

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing several programs—and an executive—from Denali Therapeutics.

The biotech, called Tenvie Therapeutics, launched Wednesday with $200 million from ARCH Venture Partners — one of Denali’s early investors — as well as F-Prime Capital, Mubadala Capital ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Stoke Therapeutics has finalized plans for a Phase ...

The company is advancing a pipeline of therapeutics, including programs acquired from Denali Therapeutics Inc., focused on treating neurological, cardiometabolic and ophthalmic diseases.

Tenvie Therapeutics Inc. is getting a set of small-molecule drugs — specifically, ones aimed at tamping down inflammation, rescuing metabolic dysfunction and restoring lysosomal function ...

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tenvie Therapeutics launched today with a commitment to transform the treatment of neurological diseases. The company combines a deep ...

ARCH Venture Partners, F-Prime Capital, and Mubadala Capital lead $200 million investment to fuel acceleration of Tenvie into a multi-clinical asset company SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 ...

ARCH Venture Partners, F-Prime Capital, and Mubadala Capital lead $200 million investment to fuel acceleration of Tenvie into a multi-clinical asset company SOUTH SAN FRANCISCO, Calif., ...